vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and STURM RUGER & CO INC (RGR). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $151.1M, roughly 1.2× STURM RUGER & CO INC). On growth, STURM RUGER & CO INC posted the faster year-over-year revenue change (3.6% vs -1.8%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $12.3M). Over the past eight quarters, STURM RUGER & CO INC's revenue compounded faster (5.1% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Sturm, Ruger & Company, Inc., better known by the shortened name Ruger, is an American firearm manufacturing company based in Southport, Connecticut, with production facilities also in Newport, New Hampshire; Mayodan, North Carolina; and Prescott, Arizona. The company was founded in 1949 by Alexander McCormick Sturm and William B. Ruger and has been publicly traded since 1969.
AMPH vs RGR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $151.1M |
| Net Profit | $24.4M | — |
| Gross Margin | 46.8% | 17.8% |
| Operating Margin | 19.4% | 2.3% |
| Net Margin | 13.3% | — |
| Revenue YoY | -1.8% | 3.6% |
| Net Profit YoY | -35.7% | — |
| EPS (diluted) | $0.51 | $0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $151.1M | ||
| Q3 25 | $191.8M | $126.8M | ||
| Q2 25 | $174.4M | $132.5M | ||
| Q1 25 | $170.5M | $135.7M | ||
| Q4 24 | $186.5M | $145.8M | ||
| Q3 24 | $191.2M | $122.3M | ||
| Q2 24 | $182.4M | $130.8M | ||
| Q1 24 | $171.8M | $136.8M |
| Q4 25 | $24.4M | — | ||
| Q3 25 | $17.4M | $1.6M | ||
| Q2 25 | $31.0M | $-17.2M | ||
| Q1 25 | $25.3M | $7.8M | ||
| Q4 24 | $38.0M | — | ||
| Q3 24 | $40.4M | $4.7M | ||
| Q2 24 | $37.9M | $8.3M | ||
| Q1 24 | $43.2M | $7.1M |
| Q4 25 | 46.8% | 17.8% | ||
| Q3 25 | 51.4% | 15.1% | ||
| Q2 25 | 49.6% | 3.9% | ||
| Q1 25 | 50.0% | 22.0% | ||
| Q4 24 | 46.5% | 22.8% | ||
| Q3 24 | 53.3% | 18.5% | ||
| Q2 24 | 52.2% | 22.3% | ||
| Q1 24 | 52.4% | 21.5% |
| Q4 25 | 19.4% | 2.3% | ||
| Q3 25 | 13.2% | -2.7% | ||
| Q2 25 | 24.2% | -15.6% | ||
| Q1 25 | 21.9% | 6.2% | ||
| Q4 24 | 24.2% | 7.8% | ||
| Q3 24 | 29.8% | 3.1% | ||
| Q2 24 | 30.3% | 6.9% | ||
| Q1 24 | 27.9% | 5.5% |
| Q4 25 | 13.3% | — | ||
| Q3 25 | 9.0% | 1.2% | ||
| Q2 25 | 17.8% | -13.0% | ||
| Q1 25 | 14.8% | 5.7% | ||
| Q4 24 | 20.4% | — | ||
| Q3 24 | 21.1% | 3.9% | ||
| Q2 24 | 20.8% | 6.3% | ||
| Q1 24 | 25.1% | 5.2% |
| Q4 25 | $0.51 | $0.22 | ||
| Q3 25 | $0.37 | $0.10 | ||
| Q2 25 | $0.64 | $-1.05 | ||
| Q1 25 | $0.51 | $0.46 | ||
| Q4 24 | $0.74 | $0.62 | ||
| Q3 24 | $0.78 | $0.28 | ||
| Q2 24 | $0.73 | $0.47 | ||
| Q1 24 | $0.81 | $0.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $92.5M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $283.8M |
| Total Assets | $1.6B | $342.0M |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $92.5M | ||
| Q3 25 | $276.2M | $80.8M | ||
| Q2 25 | $231.8M | $101.4M | ||
| Q1 25 | $236.9M | $108.3M | ||
| Q4 24 | $221.6M | $105.5M | ||
| Q3 24 | $250.5M | $96.0M | ||
| Q2 24 | $217.8M | $105.6M | ||
| Q1 24 | $289.6M | $115.3M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $283.8M | ||
| Q3 25 | $776.7M | $279.6M | ||
| Q2 25 | $757.5M | $289.3M | ||
| Q1 25 | $751.3M | $321.5M | ||
| Q4 24 | $732.3M | $319.6M | ||
| Q3 24 | $727.7M | $314.9M | ||
| Q2 24 | $713.3M | $321.5M | ||
| Q1 24 | $672.4M | $332.0M |
| Q4 25 | $1.6B | $342.0M | ||
| Q3 25 | $1.7B | $342.3M | ||
| Q2 25 | $1.6B | $349.5M | ||
| Q1 25 | $1.6B | $379.0M | ||
| Q4 24 | $1.6B | $384.0M | ||
| Q3 24 | $1.5B | $373.5M | ||
| Q2 24 | $1.5B | $376.7M | ||
| Q1 24 | $1.6B | $385.0M |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $15.5M |
| Free Cash FlowOCF − Capex | $24.6M | $12.3M |
| FCF MarginFCF / Revenue | 13.4% | 8.2% |
| Capex IntensityCapex / Revenue | 4.5% | 2.1% |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $38.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $15.5M | ||
| Q3 25 | $52.6M | $12.9M | ||
| Q2 25 | $35.6M | $14.7M | ||
| Q1 25 | $35.1M | $11.1M | ||
| Q4 24 | $29.0M | $20.0M | ||
| Q3 24 | $60.0M | $9.4M | ||
| Q2 24 | $69.1M | $18.7M | ||
| Q1 24 | $55.3M | $7.3M |
| Q4 25 | $24.6M | $12.3M | ||
| Q3 25 | $47.2M | $7.0M | ||
| Q2 25 | $25.0M | $9.1M | ||
| Q1 25 | $24.4M | $10.0M | ||
| Q4 24 | $16.6M | $16.4M | ||
| Q3 24 | $46.2M | $2.6M | ||
| Q2 24 | $63.1M | $10.1M | ||
| Q1 24 | $46.5M | $5.6M |
| Q4 25 | 13.4% | 8.2% | ||
| Q3 25 | 24.6% | 5.5% | ||
| Q2 25 | 14.3% | 6.9% | ||
| Q1 25 | 14.3% | 7.4% | ||
| Q4 24 | 8.9% | 11.2% | ||
| Q3 24 | 24.1% | 2.1% | ||
| Q2 24 | 34.6% | 7.7% | ||
| Q1 24 | 27.1% | 4.1% |
| Q4 25 | 4.5% | 2.1% | ||
| Q3 25 | 2.8% | 4.6% | ||
| Q2 25 | 6.1% | 4.2% | ||
| Q1 25 | 6.3% | 0.8% | ||
| Q4 24 | 6.7% | 2.5% | ||
| Q3 24 | 7.2% | 5.5% | ||
| Q2 24 | 3.3% | 6.6% | ||
| Q1 24 | 5.1% | 1.3% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | 8.15× | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | 1.43× | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | 1.98× | ||
| Q2 24 | 1.82× | 2.27× | ||
| Q1 24 | 1.28× | 1.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
